Fate Therapeutics Announces Presentation of FT522 Preclinical Data for Autoimmune Diseases in Late-breaking Abstract at ASGCT Annual Meeting

Off-the-shelf, CD19-targeted CAR NK Cell Product Candidate Drives Rapid and Deep Depletion of SLE Donor CD19+ B cells ADR Technology Incorporated into FT522 Induces Functional Persistence and...

Related Keywords

United States ,Baltimore ,Maryland ,San Diego ,California ,American ,Christina Tartaglia ,Nasdaq ,Stern Investor Relations Inc ,Exchange Commission ,Fate Therapeutics Inc ,American Society Of Gene ,Technology Incorporated ,Product Candidate Drives Rapid ,Deep Depletion ,Functional Persistence ,Eliminates Alloreactive Host Immune Cells ,American Society ,Cell Therapy ,Annual Meeting ,Unique Ability ,Target Multiple Pathogenic Cell Types ,Circumvent Lympho Conditioning ,Breaking Abstract Number ,Fate Therapeutic ,Fate Therapeutics ,Private Securities Litigation Reform Act ,Investor Relations ,Markets ,